NCT01690260View on ClinicalTrials.gov

Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 2, 2017

Study Completion Date

October 2, 2017

Conditions
Bone Degenerative ChangesOsteoarthritisDegenerative Disorder of Bone
Interventions
DRUG

Bone Morphogenetic Protein 2

12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.

PROCEDURE

Autologous bone graft

Autologous bone graft in connection with bone docking operation.

Trial Locations (1)

9000

Orthopaedic Surgery Research Unit, Aalborg University Hospital, Aalborg

Sponsors
All Listed Sponsors
collaborator

Medtronic

INDUSTRY

collaborator

Center for Clinical and Basic Research (CCBR A/S).

UNKNOWN

lead

Northern Orthopaedic Division, Denmark

OTHER